Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

71403 Rosetta™ 2(DE3)pLysS Competent Cells - Novagen

71403
Purchase on Sigma-Aldrich

Overview

Replacement Information

Products

Catalogue NumberPackaging Qty/Pack
71403-3 Glass bottle 0.4 ml
71403-4 Glass bottle 1 ml
Description
OverviewA common method for transformation of DNA plasmids into E. coli is the use of chemically competent cells. Although competent cells can be prepared in the laboratory, greater efficiency, reproducibility, and convenience are achieved using Novagen prepared competent cells. Novagen competent cells represent the widest selection available for protein expression. Every Novagen competent cell strain is verified for phenotype and purity, and is guaranteed for transformation efficiency.
T7 expression strains are lysogens of bacteriophage DE3, as indicated by the (DE3). These hosts carry a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in appropriate T7 expression vectors, using IPTG as an inducer.
Rosetta™ 2 host strains are BL21 derivatives designed to enhance the expression of eukaryotic proteins that contain codons rarely used in E. coli. These strains supply tRNAs for 7 rare codones (AGA, AGG, AUA, CUA, GGA, CCC, and CGG) on a compatible chloramphenicol-resistant plasmid. The tRNA genes are driven by their native promoters.

DE3 indicates that the host is a lysogen of λDE3, and therefore carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in pET vectors by induction with IPTG.

pLysS strains express T7 lysozyme, which further suppresses basal expression of T7 RNA polymerase prior to induction, thus stabilizing pET recombinants encoding target proteins that affect cell growth and viability.
Genotype: F- ompT hsdSB(rB- mB-) gal dcm (DE3) pLysSRARE2 (CamR)


This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges MilliporeSigma to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.




This product is sold for internal research use only. Any commercial use of this product, its components, and/or any derivatives thereof (including but not limited to proteins produced using the product or its components) (together and hereinafter the 'EMD Product') requires signature of a written commercial use agreement with EMD Millipore Corporation or its successor-in-interest. Commercial use shall include but not be limited to: (1) use of the EMD Product to manufacture products for sale to third parties; (2) use of the EMD Product to provide services, information, or data to third parties in exchange for consideration; (3) use of the EMD Product for therapeutic, diagnostic or prophylactic purposes (including as part of a device, chip, assay or other product); or (4) resale of the EMD Product, whether or not such EMD Product is resold for research use. Nothing contained herein shall be deemed to represent or warrant that additional third party rights are not required for use of the EMD Product. Please direct any questions on these use restrictions to: licensing@milliporesigma.com.
Catalogue Number71403
Brand Family Novagen®
References
Product Information
2 × 200 µl or 5 × 200 µl Rosetta 2(DE3)pLysS Competent Cells
2 × 2 ml or 4 × 2 mlSOC Medium
10 µlTest Plasmid
Guaranteed efficiency> 2 × 10⁶ cfu/mg
Quality LevelMQ100
Applications
Biological Information
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Dry Ice Only
Toxicity Multiple Toxicity Values, refer to MSDS
Storage ≤ -70°C
Do not freeze Ok to freeze
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
71403-3 04055977270020
71403-4 04055977270037

Documentation

Rosetta™ 2(DE3)pLysS Competent Cells - Novagen SDS

Title

Safety Data Sheet (SDS) 

Rosetta™ 2(DE3)pLysS Competent Cells - Novagen Certificates of Analysis

TitleLot Number
71403

Citations

Title
  • Anthony Argentaro, et al. (2007) Structural consequences of disease-causing mutations in the ATRX-DNMT3-DNMT3L (ADD) domain of the chromatin-associated protein ATRX. Procedings of the National Academy of Science 104, 11939-11944.
  • Rutilio A. Fratti, et al. (2007) Stringent 3Q·1R composition of the SNARE 0-layer can be bypassed for fusion by compensatory SNARE mutation or by lipid bilayer modification. Journal of Biological Chemistry 282, 14861-14867.
  • Chun J. Tsai, Sunny A. Kim and Gilbert Chu. (2007) Cernunnos/XLF promotes the ligation of mismatched and noncohesive DNA ends. Procedings of the National Academy of Science 104, 7851-7856.
  • Zhong Yu, et al. (2007) The protein that binds to DNA base J in trypanosomatids has features of a thymidine hydroxylase. Nucleic Acids Research 35, 2107-2115.
  • Debashish Ray, et al. (2006) West Nile virus 5'-cap structure is formed by sequential guanine N-7 and ribose 2'-O methylations by nonstructural protein 5. Journal of Virology 80, 8362-8370.
  • Sean Crosson, et al. (2005) Conserved modular design of an oxygen sensory/signaling network with species-specific output. Proceedings of the National Academy of Sciences (USA) 102, 8018-8023.
  • Alexander J. Ruthenburg, et al. (2005) A superhelical spiral in the Escherichia coli DNA gyrase A C-terminal domain imparts unidirectional supercoiling bias. Journal of Biological Chemistry 280, 26177-26184.
  • User Protocols

    Title
    TB009 Competent Cells
    TB053 Academic and Non-profit Laboratory Assurance Letter